Universidade Federal Fluminense           Universidade do Estado do Rio de JaneiroInstituto de Medicina Social            ...
   HEPATITIS C INFECTION IN BRAZIL   PHARMACOLOGICAL TREATMENTS   BRAZIL´S REALITY
   TO ANALYSIS THE COST-EFFECTIVENESS AND    BUDGET     IMPACT    OF      RECOMMENDED    TREATMENTS FOR ADULTS INFECTED W...
   A MARKOV MODEL   PUBLIC HEALTH SYSTEM (SUS) PERSPECTIVE   DUAL THERAPY WITH 2A ALPHA PEGUINTERFERON    VS, 2B ALPHA ...
Table 1 - Effectiveness of treatment for HCV with 2a alpha peguinterferon +                  ribavirin and 2b alpha peguin...
   Cost-effectiveness    Table 2 - Years of life gained according to the treatment strategies                            ...
Table 3 - Cost-effectiveness of strategies for hepatitis C treatment for a 1,000 patients for 30 year cohort              ...
   AS THERE WERE NO SIGNIFICANT DIFFERENCES    BETWEEN THE EFFECTIVENESS OF THE TWO    ALPHA PEGUINTERFERONS   THE     C...
   LIMITATIONS   THE RECOMMENDATION OF THE STUDY IS THAT    THE CHOICE COST-EFFECTIVE USE OF ALPHA    PEGUINTERFERON 2A ...
   CONSELHO NACIONAL DE DESENVOLVIMENTO    CIENTÍFICO E TECNOLÓGICO – CNPq   UNIVERSIDADE FEDERAL FLUMINENSE   UNIVERSI...
Upcoming SlideShare
Loading in …5
×

Economic evaluation. Treating genotype 1 chronic hepatitis C with alpha pegylated interferons (2a and 2b) and ribavirin : a cost-effectiveness analysis.

399 views
265 views

Published on

Treating genotype 1 chronic hepatitis C with alpha pegylated interferons (2a and 2b) and ribavirin : a cost-effectiveness analysis.

Published in: Health & Medicine, Travel
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
399
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Economic evaluation. Treating genotype 1 chronic hepatitis C with alpha pegylated interferons (2a and 2b) and ribavirin : a cost-effectiveness analysis.

  1. 1. Universidade Federal Fluminense Universidade do Estado do Rio de JaneiroInstituto de Medicina Social Instituto de Medicina SocialDepartamento de Saúde e Sociedade Programa de Estudos em Avaliação de Tecnologias e Economia da Saúde   Gabriela Bittencourt Gonzalez Mosegui, Cid Manso de Mello Vianna, Marcus Paulo da Silva Rodrigues, Renata de Mello Perez
  2. 2.  HEPATITIS C INFECTION IN BRAZIL PHARMACOLOGICAL TREATMENTS BRAZIL´S REALITY
  3. 3.  TO ANALYSIS THE COST-EFFECTIVENESS AND BUDGET IMPACT OF RECOMMENDED TREATMENTS FOR ADULTS INFECTED WITH GENOTYPE 1 CRONIC HEPATITIS C, BASED ON A COMPARISON OF ALPHA PEGUINTERFERON COMBINED THERAPY-ASSOCIATED 2A AND 2B AND RIBAVIRIN WITH NON-TREATMENT
  4. 4.  A MARKOV MODEL PUBLIC HEALTH SYSTEM (SUS) PERSPECTIVE DUAL THERAPY WITH 2A ALPHA PEGUINTERFERON VS, 2B ALPHA PEGUINTERFERON (BOTH WITH RIBAVIRIN) DATA MEASURES OF EFFECTIVENESS
  5. 5. Table 1 - Effectiveness of treatment for HCV with 2a alpha peguinterferon + ribavirin and 2b alpha peguinterferon + ribavirin 2a Alpha 2b Alpha peginterferon + peguinterferon + ribavirin ribavirin Sustained viral response 0,49 0,48 (SVR) Early viral response 0,81 0,76 (EVR) Probability of reaching 0,6049 0,6315 SVRSource: Malone et al, 2005. ASSUMPTIONS UTILITY MEASURES
  6. 6.  Cost-effectiveness Table 2 - Years of life gained according to the treatment strategies 2a Alpha 2b Alpha Natural Effectiveness peguinterferon peguinterferon + History + ribavirin ribavirin QUALY (5% 12,19 13,86 13,82 discount) QUALY (without 20,70 24,74 24,64 discount) QUALY (10% 8,37 9,20 9,18 discount)Costs in US dollars and effectiveness in QALYs
  7. 7. Table 3 - Cost-effectiveness of strategies for hepatitis C treatment for a 1,000 patients for 30 year cohort IncrStrategy Costs Incr Costs Effectiv C/E (ICER) EffectivNatural History 3,245.73 12.19 266.26 2a alpha PegInter 21,933.69 18,687.96 13.86 1.68 1,582.52 11,123.79 + Ribavirin 2b alpha Peginter 26,752.20 4,818.51 13.82 0.04 1,935.76 (Dominated) + RibavirinAll options related to the Natural HistoryNatural History 3,245.73 12.19 266.26 2a alpha PegInter 21,933.69 18,687.96 13.86 1.68 13,055.77 11,123.79 + Ribavirin 2b alpha Peginter 26,752.20 23,506.47 13.82 1.63 1,935.76 14,421.15 + Ribavirin Costs in US dollars and effectiveness in QALYs Quotation in 05/01/2012
  8. 8.  AS THERE WERE NO SIGNIFICANT DIFFERENCES BETWEEN THE EFFECTIVENESS OF THE TWO ALPHA PEGUINTERFERONS THE CHOICE BETWEEN ONE OR ANOTHER MEDICINE DEPENDS ON THE PRICE BEING CHARGED SENSITIVITY ANALYSIS HAS SHOWN THAT USING THE PRICE OF A DRUG IN THE OTHER, IT IMPLIES A CHANGE IN THE CONCLUSIONS ALREADY REACHED BEFORE
  9. 9.  LIMITATIONS THE RECOMMENDATION OF THE STUDY IS THAT THE CHOICE COST-EFFECTIVE USE OF ALPHA PEGUINTERFERON 2A OR 2B DEPENDS ON THE PRICE YOU CAN GET IN THE ACQUISITION OF EACH OF THESE DRUGS.
  10. 10.  CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO – CNPq UNIVERSIDADE FEDERAL FLUMINENSE UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO PROGRAMA DE ESTUDOS EM AVALIAÇÃO DE TECNOLOGIAS E ECONOMIA DA SAÚDE

×